Neuropsychiatric manifestations of systemic lupus erythematosus (NPSLE) are among the main causes of morbidity and mortality attributed to lupus activity. Conventional NPSLE treatment combines CS and immunosuppressants, but some symptoms do not respond. We retrospectively evaluated the adjunction of plasma exchanges (PE) to treat 13 NPSLE flares occurring in 10 patients (mean age, 30 years) between 1989 and 2002. NP manifestations were the first SLE symptoms for seven patients, with a mean of 3.2 NP manifestations/flare. All patients received CS and cyclophosphamide pulses. A mean of 15 PE/flare were performed. All patients improved within a mean of 3 (median: 2.5; range: 1.5—8) weeks thereafter. Complete remissions of 7/13 flares were obtained within a mean of 7 (median: 4; range: 2—22) weeks. Partial remissions were achieved for the remaining six flares, characterized by new NP manifestations during three and insufficient control of the others. Other SLE manifestations regressed for all patients with the mean European consensus lupus activity measurement score declining from pretreatment 6.9 to 1.2. A regimen combining CS, cyclophosphamide and PE is effective against severe NPSLE, with acceptable toxicity. Lupus (2007) 16, 817—822.
Kovacs B., Lafferty TL, Brent LH, DeHoratius RJTransverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis2000; 59(2):120—124.
2.
Futrell N., Schultz LR, Millikan C.Central nervous system disease in patients with systemic lupus erythematosus . Neurology1992; 42(9): 1649—1657.
3.
Jennekens FG , Kater L.The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002;41(6): 619—630.
4.
Scolding NJ, Joseph FGThe neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol2002; 28(3):173—189.
5.
West SG, Emlen W., Wener MH, Kotzin BLNeuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med1995; 99(2):153—163.
6.
Feinglass EJ , Arnett FC, Dorsch CA, Zizic TM, Stevens MBNeuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore)1976; 55(4):323—339.
7.
Jones JV, Cumming RH, Bucknall RC, Asplin CMPlasmapheresis in the management of acute systemic lupus erythematosus?Lancet1976; 1(7962):709—711.
8.
Wallace DJ, Goldfinger D., Pepkowitz SH et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis1998; 13(4):163—166.
9.
Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JMA controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med1992; 326(21):1373—1379.
10.
Unterweger B. , Klein G., Fleischhacker WWPlasma exchange for cerebral lupus erythematosus . Biol Psychiatry1988; 24:941—960.
11.
Slovick DITreatment of acute myelopathy in systemic lupus erythematosus with plasma exchange and immunosuppression. J Neurol Neurosurg Psychiatry1986; 49(1):103—105.
12.
Nectoux F., Euller-Ziegler L., Grisot C., Quaranta JF, Duplay H., Ziegler G.[Lupus chorea revealing. Study in magnetic resonance imaging. Success of plasma exchanges after resistance to pulsed cortisone]. Rev Rhum Mal Osteoartic1992; 59(6):436—438.
Bouvier M., Colson F., Tebib JG, Noël E., Schott AMFormes cliniques de “neurolupus”. Semaine des Hôpitaux de Paris1990; 66(1—2):7—11.
15.
Evans DT, Giles M., Horne DJ, d'Apice AJ, Riglar A, Toh BH. Cerebral lupus erythematosus responding to plasmaphaeresis . Postgrad Med J1981; 57(666):247—251.
16.
Marson P., Tenderini ML, Doria A., Rigoli AM, De Silvestro G.Combined plasma-exchange and immunosuppressive therapy for neurologic involvement of systemic lupus erythematosus. Recenti Prog Med1994; 85(1):72—73.
17.
Tanter Y., Rifle G., Chalopin JM, Mousson C., Besancenot JFPlasma exchange in central nervous system involvement of systemic lupus erythematosus . Plasma Ther Transfus Technol1987; 8:161—168.
18.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999; 42(4):599—608.
19.
Mosca M., Bencivelli W., Vitali C., Carrai P., Neri R., Bombardieri S.The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus2000; 9(6): 445—450.
20.
Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CHDerivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35(6):630—640.
21.
Euler HH, Schwab UM, Schroeder JO, Hasford J.The Lupus Plasmapheresis Study Group: rationale and updated interim report . Artif Organs1996; 20(4):356—359.
22.
Miyakis S., Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4(2):295—306.
23.
Wallace DJApheresis for lupus erythematosus. Lupus1999 ; 8(3):174—180.
24.
Bosch T.Current status in extracorporeal immunomodulation: immune disorders. Artif Organs1996; 20(8):902—905.
Csipo I., Kiss E., Soltesz P. et al. Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE). Clin Exp Immunol1999; 118(3):458—464.
27.
Simon J., Simon O.Effect of passive transfer of anti-brain antibodies to a normal recipient . Exp Neurol1975; 47(3):523—534.
28.
Williams RC Jr, Sugiura K., Tan EMAntibodies to microtubuleassociated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum2004; 50(4):1239—1247.
29.
Ochola J., Hussain M., Khamashta M., Hughes GR, Vergani D.Detection of brain-reactive autoantibodies in the sera of patients with systemic lupus erythematosus and cerebral involvement. J Immunol Methods1995; 185(2):259—261.
30.
Wilson WA, De Ceulaer K, Morgan AGSickle cell anemia, complement, and systemic lupus erythematosus. Arthritis Rheum1979; 22(7):803.
31.
Bonfa E., Golombek SJ, Kaufman LD et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med1987; 317(5):265—271.
32.
Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JASerum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis1990; 49(4):249—253.
33.
Denburg SD, Behmann SA, Carbotte RM, Denburg JALymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum1994; 37(3):369—375.
34.
How A., Dent PB, Liao SK, Denburg JAAntineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum1985; 28(7):789—795.
Dean GS, Tyrrell-Price J., Crawley E., Isenberg DACytokines and systemic lupus erythematosus. Ann Rheum Dis2000; 59(4):243—251.
37.
Haas C., Ryffel B, LeHir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW)F1 mice. J Immunol1998; 160(8):3713—3718.
38.
Trysberg E. , Carlsten H., Tarkowski A.Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus2000; 9(7):498—503.
Yajima N., Kasama T., Isozaki T. et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum2005; 52(6):1670—1675.
41.
Boumpas DT, Yamada H., Patronas NJ, Scott D., Klippel JH, Balow JEPulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med1991; 81(296):975—984.
42.
De Bandt M, Goycochea MV, Meyer O. et al. [Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations] . Ann Méd Interne (Paris) 1994; 145(2):75—87.
43.
Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GRPulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol1996; 14(3):295—299.
44.
Neuwelt CM, Lacks S., Kaye BR, Ellman JB, Borenstein DGRole of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med1995 ; 98(1):32—41.
45.
Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L. et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis2005; 64(4):620—625.
46.
Sherer Y., Levy Y., Langevitz P., Lorber M., Fabrizzi F., Shoenfeld Y.Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol1999; 18(2):170—173.
47.
Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., Tanaka Y.Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus2003; 12(10): 798—800.
48.
Smith GM, Leyland MJ, Gibberd FBPlasma exchange for cerebral lupus erythematosus. Lancet1987; 329 (8524):103.
49.
Devinsky O. , Petito CK, Alonso DRClinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol1988; 23(4):380—384.
50.
Hanly JG, Hong C., Smith S., Fisk JDA prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum1999; 42(4):728—734.
51.
Liou HH, Wang CR, Chen CJ et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus1996; 5(4):307—312.
